Related references
Note: Only part of the references are listed.Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model
Asahi Ito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
AllergoOncology: the role of IgE-mediated allergy in cancer
E. Jensen-Jarolim et al.
ALLERGY (2008)
Novel human antibody therapeutics: The age of the Umabs
Sigrid R. Ruuls et al.
Biotechnology Journal (2008)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
T. Shantha Raju
CURRENT OPINION IN IMMUNOLOGY (2008)
Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response
Lvdie Cassard et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Optimizing engagement of the immune system by anti-timor antibodies: an engineer's perspective
John R. Desjarlais et al.
DRUG DISCOVERY TODAY (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Outlook - Development trends for monoclonal antibody cancer therapeutics
Janice M. Reichert et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity
Kazuhiro Masuda et al.
MOLECULAR IMMUNOLOGY (2007)
Humanized mice in translational biomedical research
Leonard D. Shultz et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Antibody constructs in cancer therapy - Protein engineering strategies to improve exposure in solid tumors
Robert A. Beckman et al.
CANCER (2007)
Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-hodgkin lymphoma
Daniel E. Lopes de Menezes et al.
JOURNAL OF IMMUNOTHERAPY (2007)
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
Khuda D. Khan et al.
CLINICAL CANCER RESEARCH (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Development of recombinant human polyclonal antibodies for the treatment of complex human diseases
Anne B. Tolstrup et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Divergent immunoglobulin G subclass activity through selective Fc receptor binding
F Nimmerjahn et al.
SCIENCE (2005)
FcγRIV:: A novel FcR with distinct IgG subclass specificity
F Nimmerjahn et al.
IMMUNITY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism
R Niwa et al.
CLINICAL CANCER RESEARCH (2004)
Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship
S Dall'Ozzo et al.
CANCER RESEARCH (2004)
A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies
CI Spiridon et al.
CLINICAL CANCER RESEARCH (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Inflammation in autoimmunity: receptors for IgG revisited
HM Dijstelbloem et al.
TRENDS IN IMMUNOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
